Journal of the American College of Cardiology

Papers
(The H4-Index of Journal of the American College of Cardiology is 104. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–20195481
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure1060
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease955
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization700
The Global Burden of Cardiovascular Diseases and Risk653
2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction627
2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary613
STS-ACC TVT Registry of Transcatheter Aortic Valve Replacement588
Valve Academic Research Consortium 3: Updated Endpoint Definitions for Aortic Valve Clinical Research536
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy424
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary409
2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR Guideline for the Evaluation and Diagnosis of Chest Pain403
Preeclampsia—Pathophysiology and Clinical Presentations370
Anticoagulation, Bleeding, Mortality, and Pathology in Hospitalized Patients With COVID-19365
The Global Burden of Cardiovascular Diseases and Risks341
Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction308
Characterization of Myocardial Injury in Patients With COVID-19306
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies298
Interpreting the Kansas City Cardiomyopathy Questionnaire in Clinical Trials and Clinical Care294
Remnant Cholesterol, Not LDL Cholesterol, Is Associated With Incident Cardiovascular Disease292
Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation283
Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases276
The ARIC (Atherosclerosis Risk In Communities) Study258
2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Pl250
Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease235
Registry of Arterial and Venous Thromboembolic Complications in Patients With COVID-19227
Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy227
Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk224
Machine Learning and the Future of Cardiovascular Care223
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy216
Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis215
Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction215
2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk213
Echocardiographic Findings in Pediatric Multisystem Inflammatory Syndrome Associated With COVID-19 in the United States189
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary186
Global Burden of Cardiovascular Diseases and Risks, 1990-2022183
Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis182
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients178
2020 ACC Expert Consensus Decision Pathway for Anticoagulant and Antiplatelet Therapy in Patients With Atrial Fibrillation or Venous Thromboembolism Undergoing Percutaneous Coronary Intervention or Wi176
2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary175
Management of Hypertrophic Cardiomyopathy174
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis172
Coronavirus and Cardiovascular Disease, Myocardial Injury, and Arrhythmia171
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy170
Inflammation, Aging, and Cardiovascular Disease168
Interventions for Frailty Among Older Adults With Cardiovascular Disease167
2022 ACC/AHA Guideline for the Diagnosis and Management of Aortic Disease167
Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy167
Impact of Plaque Burden Versus Stenosis on Ischemic Events in Patients With Coronary Atherosclerosis166
2021 ACC Expert Consensus Decision Pathway on the Management of ASCVD Risk Reduction in Patients With Persistent Hypertriglyceridemia166
Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19163
Cardiovascular Deaths During the COVID-19 Pandemic in the United States162
Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation161
Pathophysiology of Takotsubo Syndrome158
Impact of COVID-19 Pandemic on Mechanical Reperfusion for Patients With STEMI153
Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis152
Cardiac Involvement in Fabry Disease149
Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19147
Post-Stroke Cardiovascular Complications and Neurogenic Cardiac Injury144
4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation144
Percutaneous Coronary Intervention for Vulnerable Coronary Atherosclerotic Plaque141
Medial Arterial Calcification139
Heart Failure With Preserved Ejection Fraction136
Mitochondria-Rich Extracellular Vesicles From Autologous Stem Cell–Derived Cardiomyocytes Restore Energetics of Ischemic Myocardium136
Short-Term Exposure to Ambient Air Pollution and Mortality From Myocardial Infarction136
Cardiac Rehabilitation for Patients With Heart Failure135
Sleep Disordered Breathing and Cardiovascular Disease135
2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction135
Global Burden of Cardiovascular Diseases and Risks Collaboration, 1990-2021134
International Impact of COVID-19 on the Diagnosis of Heart Disease134
Dietary Inflammatory Potential and Risk of Cardiovascular Disease Among Men and Women in the U.S.134
Global Chronic Total Occlusion Crossing Algorithm133
Challenges in Cardiac and Pulmonary Sarcoidosis133
Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion133
Therapeutic Potential of Ketone Bodies for Patients With Cardiovascular Disease132
Type A Aortic Dissection—Experience Over 5 Decades129
Atherosclerotic Carotid Plaque Composition and Incident Stroke and Coronary Events129
Clonal Hematopoiesis and Risk of Progression of Heart Failure With Reduced Left Ventricular Ejection Fraction128
Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates126
Right Ventricular-Pulmonary Arterial Coupling and Afterload Reserve in Patients Undergoing Transcatheter Tricuspid Valve Repair126
Structural Deterioration of Transcatheter Versus Surgical Aortic Valve Bioprostheses in the PARTNER-2 Trial126
3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure122
Inhibition of Interleukin-1β and Reduction in Atherothrombotic Cardiovascular Events in the CANTOS Trial122
Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction121
Association of Clonal Hematopoiesis With Incident Heart Failure120
2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation120
Ultra-Processed Foods and Incident Cardiovascular Disease in the Framingham Offspring Study120
Criteria for Defining Stages of Cardiogenic Shock Severity119
VLDL Cholesterol Accounts for One-Half of the Risk of Myocardial Infarction Associated With apoB-Containing Lipoproteins119
Triglycerides and Residual Atherosclerotic Risk114
Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice113
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload112
Kidney Function and Outcomes in Patients Hospitalized With Heart Failure111
Management and Outcomes of Cardiogenic Shock in Cardiac ICUs With Versus Without Shock Teams111
Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure111
2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease108
Coronary In-Stent Restenosis108
Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor–Associated Myocarditis107
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension106
2020 ACC Expert Consensus Decision Pathway on Management of Conduction Disturbances in Patients Undergoing Transcatheter Aortic Valve Replacement106
Mechanical Left Ventricular Unloading in Patients Undergoing Venoarterial Extracorporeal Membrane Oxygenation106
Exercise Intolerance in Older Adults With Heart Failure With Preserved Ejection Fraction105
Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment105
Transcatheter Mitral Valve Therapy in the United States104
0.2179319858551